Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update

Southern African Journal of HIV Medicine

Volumn 14, Issue 2, 2013, Pages 76-86

  Govender, N P ^a   Meintjes, G ^a   Bicanic, T ^a   Dawood, H ^a   Harrison, T S ^a   Jarvis, J N ^a   Karstaedt, A S ^a   Maartens, G ^a   McCarthy, K M ^a   Rabie, H ^a   Variava, E ^a   Venter, W D F ^a   Boulware, D R ^a   Chiller, T ^a   Meya, D B ^a   Scriven, J ^a  

^a Southern African HIV Clinicians Society   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE; HYDROCORTISONE; MAGNESIUM CHLORIDE; MORPHINE; NEVIRAPINE; PARACETAMOL; POTASSIUM CHLORIDE; PREDNISONE; RIFAMPICIN; VORICONAZOLE;

ABDUCENS NERVE PARALYSIS; AMNESIA; ANEMIA; ANTIFUNGAL SUSCEPTIBILITY; BRAIN SCINTISCANNING; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONFUSION; CONSCIOUSNESS DISORDER; CONSOLIDATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIET SUPPLEMENTATION; DIPLOPIA; DRUG MEGADOSE; EARLY DIAGNOSIS; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; FEVER; FLUID THERAPY; HEADACHE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; LIVER INJURY; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUROIMAGING; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OUTPATIENT; PAPILLEDEMA; PATIENT REFERRAL; PHLEBITIS; PHYSICIAN; PRACTICE GUIDELINE; RELAPSE; SCREENING; SOUTH AFRICA; TREATMENT DURATION; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION;

EID: 84881336090     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.930     Document Type: Conference Paper

References (42)

1. McCarthy K, Meintjies G, Arthington-Skaggs B, et al. Guidelines for the Diagnosis, Management and Prevention of Cryptococcal Meningitis and Disseminated Cryptococcosis in HIV-infected patients. Southern African Journal of HIV Medicine 2007;8(3):25-35.
2. National Institute for Communicable Diseases. GERMS-SA Annual Report 2011. Johannesburg: National Institute for Communicable Diseases, 2012.
3. World Health Organization. Rapid Advice - Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva: World Health Organization, 2011. http://www.who.int/hiv/pub/ cryptococcal-disease2011/en/ (accessed 7 May 2013).
4. Govender NP, Chetty V, Roy M, et al. Phased implementation of screening for cryptococcal disease in South Africa. S Afr Med J 2012;102:914-917. [http://dx.doi.org/10.7196/samj.6228]
5. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a Novel Point of Care Cryptococcal Antigen (CRAG) Test on Serum, Plasma and Urine from Patients with HIV-associated Cryptococcal Meningitis. Clin Infect Dis 2011;53:1019-1023. [http://dx.doi. org/10.1093/cid/cir613]
6. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009;48:1775-1783. [http://dx.doi. org/10.1086/599112]
7. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial. Clin Infect Dis 2008;47:123-130. [http://dx.doi.org/10.1086/588792]
8. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012;54:121-128. [http://dx.doi.org/10.1093/cid/cir745]
9. Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368:1291-1302. [http://dx.doi. org/10.1056/NEJMoa1110404].
10. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010;50:1532-1538. [http://dx.doi. org/10.1086/652652]
11. Boulware DR, Meya D, Muzoora C, et al. ART Initiation within the First 2 Weeks of Cryptococcal Meningitis Is Associated with Higher Mortality: A Multisite Randomized Trial. 20th Conference on Retroviruses and Opportunistic Infections (Abstract number 144), 3-6 March 2013, Atlanta, GA, USA.
12. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-1701. [http://dx.doi.org/10.1086/533468]
13. Govender N, Cohen C, Meiring S, et al. Trends in Treatment of Adults with Incident Cryptococcosis, South Africa, 2005-2008. In Abstracts and Programme: 17th Conference on Retroviruses and Opportunistic Infections (Abstract number 800), 16-19 February 2010, San Francisco, CA, USA.
14. National Department of Health. The South African Antiretroviral Treatment Guidelines - 2013. Pretoria: National Department of Health, 2013. http://www.doh.gov.za/docs/policy/2013/ART-Treatment-Guidelines-Final- 25March2013.pdf (accessed 9 May 2013).
15. Meintjes G, Maartens G, Boulle A, et al. Guidelines for Antiretroviral Treatment in Adults. Southern African Journal of HIV Medicine 2013;13(1):114-133.
16. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, Van RA. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: A prospective cohort study. J Int AIDS Soc 2009;12:38. [http://dx.doi. org/10.1186/1758-2652-12-38]
17. Jarvis JN, Lawn S, Vogt M, Bangani N, Wood R, Harrison TS. Screening for Cryptococcal Antigenaemia Among Patients in an Antiretroviral Treatment Program in South Africa. Clin Infect Dis 2009;48:856-862. [http://dx.doi. org/10.1086/597262]
18. + cell count ≤ 100 cells/μL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010;51:448-455. [http://dx.doi. org/10.1086/655143]
19. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012;59:e85-e91. [http://dx.doi. org/10.1097/QAI.0b013e31824c837e]
20. Jarvis JN, Lawn SD, Wood R, Harrison TS. Cryptococcal antigen screening for patients initiating antiretroviral therapy: Time for action. Clin Infect Dis 2010;51:1463-1465. [http://dx.doi. org/10.1086/657405]
21. Meiring ST, Quan VC, Cohen C, et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005-2007. AIDS 2012;26:2307-2314. [http://dx.doi.org/10.1097/QAD.0b013e3283570567]
22. Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town. South African Medicines Formulary - Tenth Edition. Cape Town: Health and Medical Publishing Group, 2012.
23. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010;10:67. [http://dx.doi.org/10.1186/1471- 2334-10-67]
24. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006;20:2199-2206.
25. Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J 2010;100:378-382.
26. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002;21:54-56.
27. McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLOS ONE 2012;7:e49541. [http://dx.doi.org/10.1371/journal. pone.0049541]
28. Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother 2011;55:2606-2611. [http://dx.doi.org/10. 1128/AAC.00048-11]
29. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-792.
30. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322. [http://dx.doi.org/10.1086/649858]
31. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80.
32. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV associated cryptococcal meningitis: A randomised trial. Lancet 2004;363:1764-1767.
33. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004;43:725-732.
34. Day JN. A randomized, double blind, placebocontrolled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis. Current Controlled Trials ISRCTN59144167. [http://dx.doi.org/10.1186/ ISRCTN59144167]
35. Th eron E. Development of a tool to ensure correct stock management and accurate administration of intravenous amphotericin B. S Afr Pharmaceut J 2009:40-42.
36. Bisson GP, Molefi M, Bellamy S, et al. Early Versus Delayed Antiretroviral Th erapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis. Clin Infect Dis 2013;56:1165-1173. [http://dx.doi.org/10.1093/cid/cit019]
37. Wakeham K, Parkes-Ratanshi R, Watson V, Ggayi AB, Khoo S, Lalloo DG. Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010;65:316-319. [http://dx.doi.org/10.1093/jac/dkp451]
38. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007;7:14.
39. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Th e NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30:47-54.
40. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010;10:791-802. [http://dx.doi.org/10.1016/S1473-3099(10)70170-5]
41. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: A prospective study. J Acquir Immune Defic Syndr 2009;51:130-134. [http://dx.doi.org/10.1097/QAI. 0b013e3181a56f2e]
42. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and metaanalysis. Lancet Infect Dis 2010;10:251-261. [http://dx.doi.org/10.1016/S1473-3099(10)70026-8]